Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study

Norio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, Satoshi Saito, Nozomu Muraishi, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada – 16 May 2022 – The aim of this study was to determine the impact at 5 years of sodium‐glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) on liver histopathology and clinical features.

Code of Conduct

The AASLD Communities, Liver Connect forums, (“AASLD Communities” or “Community” or “Liver Connect”) is a service provided by the American Association for the Study of Liver Diseases (referred to as “AASLD,” “we,” “our,” or “us”) for its members. 

Thank you for being part of Liver Connect forums. To ensure the best possible experience for all members, we have established this Code of Conduct governing your participation.

Who We Are

AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. We foster research that leads to improved treatment options for millions of liver disease patients. We advance the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.

Fellows Program

The Fellow of the American Association for the Study of Liver Diseases (FAASLD) — the highest honor among AASLD membership categories — recognizes superior professional achievement in clinical or academic practice, and in basic or clinical research.

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial

Masato Yoneda, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Takaomi Kessoku, Kento Imajo, Asako Nogami, Masataka Taguri, Hiroyuki Kirikoshi, Satoru Saito, Atsushi Nakajima – 15 May 2022 – The incidence of nonalcoholic fatty liver disease (NAFLD) has recently increased and is related to obesity and the associated surge in type 2 diabetes mellitus (T2DM) and metabolic syndromes. This trial follows up on our previous work and forms part of the ToPiND study. We aimed to combine tofogliflozin and pioglitazone treatment for hepatic steatosis in patients with NAFLD and T2DM.

CAQ Corner: Surgical evaluation for liver transplantation

Asish C. Misra, Juliet Emamaullee – 15 May 2022 – The evaluation of a liver transplantation candidate is a complex and detailed process that in many cases must be done in an expedited manner because of the critically ill status of some patients with end‐stage liver disease. It involves great effort from and the collaboration of multiple disciplines, and during the evaluation several studies and interventions are performed to assess and potentially prepare a patient for liver transplant. Here we review the liver transplantation evaluation from a surgical perspective.

Subscribe to